Amgen defeats Novartis appeal over arthritis drug Enbrel's patents – Reuters

Amgen defeats Novartis appeal over arthritis drug Enbrel’s patents – Reuters

A federal appeals court on Wednesday upheld two patents for Amgen Inc’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG’s effort to void the patents.

Read More…

You May Also Like